Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer
暂无分享,去创建一个
A. Özer | M. Akkiprik | Mustafa Akkiprik | Ebubekir Dirican | Ayşe Özer | E. Dirican | Mustafa Akkiprik
[1] M. Troxell,et al. Novel method for PIK3CA mutation analysis: locked nucleic acid--PCR sequencing. , 2013, The Journal of molecular diagnostics : JMD.
[2] B. Park,et al. Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. , 2015, Clinical biochemistry.
[3] G. Mills,et al. PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer , 2011, Molecular Cancer Therapeutics.
[4] A. Lash,et al. Frequent Mutation of the PIK3CA Gene in Ovarian and Breast Cancers , 2005, Clinical Cancer Research.
[5] Li Zhao,et al. Oncogenic PI3K deregulates transcription and translation , 2005, Nature Reviews Cancer.
[6] S. Chandarlapaty,et al. Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer , 2012, Clinical Cancer Research.
[7] C. Arteaga,et al. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. , 2002, Seminars in oncology.
[8] A. Janecka,et al. Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting. , 2015, Polish journal of pathology : official journal of the Polish Society of Pathologists.
[9] Analysing the mutational status of PIK3CA in circulating tumor cells from metastatic breast cancer patients , 2013, Molecular oncology.
[10] S. Bicciato,et al. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. , 2015, The oncologist.
[11] M. Sliwkowski,et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. , 2009, Cancer cell.
[12] B. Park,et al. Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients , 2013, Cancer biology & therapy.
[13] Jong Soon Kang,et al. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration‐resistant prostate cancer , 2015, The Prostate.
[14] M. Troxell,et al. Frequent PIK3CA Mutations in Radial Scars , 2013, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[15] Pixu Liu,et al. Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.
[16] I. Weinstein,et al. The origins of human cancer: molecular mechanisms of carcinogenesis and their implications for cancer prevention and treatment--twenty-seventh G.H.A. Clowes memorial award lecture. , 1988, Cancer research.
[17] Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies , 2009, British Journal of Cancer.
[18] Massimo Libra,et al. PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches , 2009, Cell cycle.
[19] T. Wilson,et al. Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer , 2014, Breast Cancer Research and Treatment.
[20] Rosette Lidereau,et al. PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups , 2012, Breast Cancer Research.
[21] C. George Priya Doss,et al. Deciphering the impact of somatic mutations in exon 20 and exon 9 of PIK3CA gene in breast tumors among Indian women through molecular dynamics approach , 2016, Journal of biomolecular structure & dynamics.
[22] J. Meyerhardt,et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer , 2009, British Journal of Cancer.
[23] I. Campbell,et al. The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. , 2001, Cancer research.
[24] A. Laenkholm,et al. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] E. Ratner,et al. PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas , 2015, British Journal of Cancer.
[26] R. Weinberg,et al. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. , 1989, Cancer research.
[27] S. Raju,et al. Phosphatidylinositol 3-kinase (PI3KCA) oncogene mutation analysis and gene expression profiling in primary breast cancer patients. , 2013, Asian Pacific journal of cancer prevention : APJCP.
[28] Hanina Hibshoosh,et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.
[29] R. Weigel,et al. Ligand-dependent Interaction of Estrogen Receptor-α with Members of the Forkhead Transcription Factor Family* , 2001, The Journal of Biological Chemistry.
[30] S. Shouman. Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells , 2015 .
[31] Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response , 2015, Breast Cancer Research.
[32] T. Krech,et al. Oncogenic PIK3CA mutations in lobular breast cancer progression , 2013, Genes, chromosomes & cancer.
[33] Keda Yu,et al. Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer. , 2014, Cancer research.
[34] Ben H. Park,et al. Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood , 2012, Clinical Cancer Research.
[35] Qun Zhou,et al. Adipocyte activation of cancer stem cell signaling in breast cancer. , 2015, World journal of biological chemistry.
[36] Gary L Gallia,et al. PIK3CA Gene Mutations in Pediatric and Adult Glioblastoma Multiforme , 2006, Molecular Cancer Research.
[37] B. Vanhaesebroeck,et al. The emerging mechanisms of isoform-specific PI3K signalling , 2010, Nature Reviews Molecular Cell Biology.
[38] Y. Zhang,et al. PIK3CA mutations are a predictor of docetaxel plus epirubicin neoadjuvant chemotherapy clinical efficacy in breast cancer. , 2014, Neoplasma.
[39] Pingzhao Hu,et al. Ras Signaling Is a Key Determinant for Metastatic Dissemination and Poor Survival of Luminal Breast Cancer Patients. , 2015, Cancer research.
[40] P. Petrow,et al. PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients , 2015, Clinical Cancer Research.
[41] Jacob D. Jaffe,et al. Abstract 1: Oncogenic extracellular domain mutations of ERBB2 in cancer , 2012 .
[42] S. Loi,et al. PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data , 2014, Breast Cancer Research.
[43] L. Cantley,et al. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation , 1985, Nature.
[44] A. Schneeweiss,et al. Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane–Anthracycline Containing Chemotherapy—DAFNE (GBG-70) , 2015, Clinical Cancer Research.
[45] Jos Jonkers,et al. Genetically engineered mouse models of PI3K signaling in breast cancer , 2013, Molecular oncology.
[46] S. Fox,et al. Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations , 2014, British Journal of Cancer.
[47] L. Cantley,et al. Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[48] H. Seow,et al. Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line. , 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[49] Jeffrey A. Engelman,et al. Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.
[50] M. Pestrin,et al. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients , 2015, Molecular oncology.
[51] M. Troxell,et al. PIK3CA-AKT pathway mutations in micropapillary breast carcinoma. , 2013, Human pathology.
[52] E. Nexo,et al. Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases , 2013, SpringerPlus.
[53] Bing Wang,et al. Multiplex detection of DNA mutations by the fluorescence fingerprint spectrum technique. , 2013, Angewandte Chemie.
[54] Sandeep Reddy,et al. Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications. , 2015, Clinical breast cancer.
[55] I. Peker,et al. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer. , 2014, Asian Pacific journal of cancer prevention : APJCP.
[56] Lu Wang,et al. PIK3CA and TP53 Gene Mutations in Human Breast Cancer Tumors Frequently Detected by Ion Torrent DNA Sequencing , 2014, PloS one.
[57] M. Rubin,et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. , 2013, European urology.
[58] R. Copeland,et al. Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase , 2008 .
[59] S. Fox,et al. Down-Regulation of Phosphatidylinositol 3′-Kinase/AKT/Molecular Target of Rapamycin Metabolic Pathway by Primary Letrozole-Based Therapy in Human Breast Cancer , 2008, Clinical Cancer Research.
[60] L. Ellwein,et al. Cell proliferation in carcinogenesis. , 1990, Science.
[61] Razelle Kurzrock,et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] R. Bast,et al. Holland-Frei Cancer Medicine , 2016 .
[63] J. Baselga,et al. Management of breast cancer with targeted agents: importance of heterogenicity , 2010, Nature Reviews Clinical Oncology.
[64] Aiko Sueta,et al. An Integrative Analysis of PIK3CA Mutation, PTEN, and INPP4B Expression in Terms of Trastuzumab Efficacy in HER2-Positive Breast Cancer , 2014, PloS one.
[65] Yuval Inbar,et al. Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit , 2007, Science.
[66] L. Skoog,et al. PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer , 2007, Clinical Cancer Research.
[67] M. Mandal,et al. Breast Cancer: Classification Based on Molecular Etiology Influencing Prognosis and Prediction , 2011 .
[68] J. Bergh,et al. mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells. , 2015, Cancer letters.
[69] C. Martin. 2015 , 2015, Les 25 ans de l’OMC: Une rétrospective en photos.
[70] H. Aslam,et al. Carcinogenesis of PIK3CA , 2013, Hereditary Cancer in Clinical Practice.
[71] Carsten Denkert,et al. Analysis of PIK3CA Mutations in Breast Cancer Subtypes , 2014, Applied immunohistochemistry & molecular morphology : AIMM.
[72] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[73] R. Bernards,et al. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] G. Rewcastle,et al. Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth , 2015, Front. Oncol..
[75] Jingjing Liu,et al. Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells , 2015, Cell Death and Disease.
[76] J. Olson,et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. , 2009, Cancer research.
[77] C. Sotiriou,et al. Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer , 2013, Journal of the National Cancer Institute.
[78] R. Copeland,et al. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. , 2008, The Biochemical journal.
[79] Xuexi Yang,et al. Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients. , 2012, Asian Pacific journal of cancer prevention : APJCP.
[80] M. Ranson. Epidermal growth factor receptor tyrosine kinase inhibitors , 2004, British Journal of Cancer.
[81] S. Noguchi,et al. PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients , 2015, Breast Cancer Research and Treatment.
[82] Reiko Nishihara,et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. , 2012, The New England journal of medicine.
[83] M. Ando,et al. Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[84] N. Lindeman,et al. PIK3CA Mutations are Common in Many Tumor Types and are Often Associated With Other Driver Mutations , 2016, Applied immunohistochemistry & molecular morphology : AIMM.
[85] B. Evers,et al. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. , 2012, The Journal of surgical research.
[86] A. Spurdle,et al. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. , 2013, Gynecologic oncology.
[87] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[88] W. Gerald,et al. PIK3CA Mutation Associates with Improved Outcome in Breast Cancer , 2009, Clinical Cancer Research.
[89] Mark J. Ratain,et al. Tumour heterogeneity in the clinic , 2013, Nature.
[90] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[91] Ji Luo,et al. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.
[92] P. Hawkins,et al. PI3K Class IB Pathway in Neutrophils , 2007, Science's STKE.
[93] J. Merlin,et al. Analysis of PIK3CA exon 9 and 20 mutations in breast cancers using PCR-HRM and PCR-ARMS: correlation with clinicopathological criteria. , 2013, Oncology reports.
[94] H. Gogas,et al. Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study , 2015, PloS one.
[95] Takeshi Yamaguchi,et al. Comprehensive DNA Methylation and Extensive Mutation Analyses of HER2-Positive Breast Cancer , 2015, Oncology.
[96] Lu Shi. Racial differences in breast cancer patterns. , 2010, Science.
[97] D. Rea,et al. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[98] R. Vadlamudi,et al. Role of Estrogen Receptor Signaling in Breast Cancer Metastasis , 2011, International journal of breast cancer.
[99] S. Sleijfer,et al. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen , 2013, Breast Cancer Research and Treatment.
[100] B. Park,et al. Mutation of the PIK3CA oncogene in human cancers , 2006, British Journal of Cancer.
[101] S. Paik,et al. Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[102] H. Gómez,et al. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers. , 2014, Hematology/oncology and stem cell therapy.
[103] E. Winer,et al. Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer , 2014, Breast Cancer Research and Treatment.
[104] Zhi Hu,et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.
[105] Xiao-bin Cui,et al. Compound HRAS/PIK3CA mutations in Chinese patients with alveolar rhabdomyosarcomas. , 2014, Asian Pacific journal of cancer prevention : APJCP.
[106] S. Toyoshima,et al. Evaluation of PTEN loss and PIK3CA mutations and their correlation with efficacy of trastuzumab treatment in HER2-positive metastatic breast cancer: A retrospective study (KBC-SG 1001). , 2013, Molecular and clinical oncology.
[107] PIK3CA mutations are frequently observed in BRCAX but not BRCA2 -associated male breast cancer , 2013, Breast Cancer Research.
[108] Arasambattu Kannan Munirajan,et al. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. , 2008, International journal of oncology.
[109] Michael G. Kharas,et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer , 2015, Science Translational Medicine.
[110] R. Kimmig,et al. Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients , 2013, Breast Cancer Research and Treatment.
[111] H. Klocker,et al. Genetic alterations in the PI3K pathway in prostate cancer. , 2009, Anticancer research.
[112] K. Okkenhaug. Signaling by the phosphoinositide 3-kinase family in immune cells. , 2013, Annual review of immunology.
[113] Yuan Qi,et al. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers , 2012, Breast Cancer Research and Treatment.
[114] G. Mills,et al. Oncogenic PIK 3 CA-driven mammary tumors frequently recur via PI 3 K pathway – dependent and PI 3 K pathway – independent mechanisms , 2011 .
[115] Gordon B Mills,et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors , 2014, Breast Cancer Research.
[116] I. Cree,et al. Targeting EGFR and PI3K pathways in ovarian cancer , 2012, British Journal of Cancer.
[117] S. Chandarlapaty,et al. PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ—Implications for Progression to Invasive Breast Carcinoma , 2014, Clinical Cancer Research.
[118] C. Denny,et al. Molecular mechanisms of cancer. , 1991, The Western journal of medicine.
[119] B. Vanhaesebroeck,et al. Glucose-Potentiated Chemotaxis in Human Vascular Smooth Muscle Is Dependent on Cross-Talk Between the PI3K and MAPK Signaling Pathways , 2004, Circulation research.
[120] Q. Lv,et al. Correlation between Activation of PI3K/AKT/mTOR Pathway and Prognosis of Breast Cancer in Chinese Women , 2015, PloS one.
[121] Kai Yuan,et al. Phospho-PRAS40Thr246 predicts trastuzumab response in patients with HER2-positive metastatic breast cancer , 2014, Oncology letters.
[122] W. Jochum,et al. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract , 2008, Genes, chromosomes & cancer.
[123] Hong Sun,et al. Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing , 2015, Human Genomics.
[124] J. L. Tang,et al. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[125] I. Bièche,et al. Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab , 2013, British Journal of Cancer.
[126] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[127] A. Jimeno,et al. New phosphatidylinositol 3-kinase inhibitors for cancer , 2011, Expert opinion on investigational drugs.
[128] N. Demartines,et al. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib , 2011, Molecular Cancer.
[129] M. Dowsett,et al. Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition , 2014, Breast Cancer Research.
[130] M. Nagai,et al. PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients , 2012, Clinics.
[131] Carsten Denkert,et al. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[132] B. Neel,et al. The docking molecule gab2 is induced by lymphocyte activation and is involved in signaling by interleukin-2 and interleukin-15 but not other common gamma chain-using cytokines. , 2000, The Journal of biological chemistry.
[133] J. Engelman,et al. The PI3K pathway as drug target in human cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[134] M. Westphal,et al. Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases. , 2013, The American journal of pathology.
[135] J. Engelman,et al. Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. , 2015, Cancer cell.
[136] K. Blackwell,et al. Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor , 2015, Breast Cancer Research and Treatment.